66P - Histology and molecular characteristics of pregnancy associated breast cancer

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Cancer in Pregnancy
Breast Cancer
Pathology/Molecular Biology
Presenter Zorica Tomasevic
Citation Annals of Oncology (2015) 26 (suppl_3): 15-24. 10.1093/annonc/mdv117
Authors Z. Tomasevic1, Z. Milovanovic2, Z.M. Tomasevic1, I. Bozovic Spasojevic1, S. Milosevic1, Z. Zdrale1, N. Andjelic Dekic1, Z. Kovac3
  • 1Daily Chemotherapy Hospital, Institute of Oncology and Radiology of Serbia, 11000 - Belgrade/RS
  • 2Pathology Department, Institute of Oncology and Radiology of Serbia, 11000 - Belgrade/RS
  • 3Radiology Department, Institute of Oncology and Radiology of Serbia, 11000 - Belgrade/RS



Background: Pregnancy is considered as protective factor for breast cancer (BC) development. Although rarely some women still develop BC during or up to 12 months after pregnancy. However, other authors defined pregnancy associated BC even if developed up to 36 months after pregnancy and that definition is accepted in this analysis. The aim of this prospective study is to analyze molecular characteristics of pregnancy associated BC (PABC) diagnosed in patients up to 40 years of age. Patient's personal and familiar anamnesis for all malignancies (FAM) has also been analyzed.

Patients and methods: 39 patients with PABC were prospectively registered in 3 years interval (January 2012 - December 2014). All patients had confirmed invasive BC diagnosed during or up to 36 months after pregnancy.

Results: Median age of patients was 31 years (24-40), median time from pregnancy was 20 months (20-36).PABC was diagnosed during or immediately after pregnancy (up to 3 months) in 10 pts (25,6%).Two patients (5.1%) had Hodgkin disease in adolescence (14, and 18 years before PABC). FAM was known for 28 pts (70%): 8/16 pts with positive FAM had one or more relatives with BC or ovarian cancer.

Histology findings were: Ductal carcinoma 58.4%; Lobular 20.5%; Inflammatory breast cancer with confirmed lymphangiosis 15,3%; other histology types 5.1%. Initial stage at the time of PABC was: Stage I, II 18/39 (46.1%); Stage III 17/39 (43.5%): Stage IV 4/39 (10.2%). Molecular PABC characteristics are shown below:

PABC molecular type HER2 3+ 28.2% Triple negative 30.7% ER + /HER2- 41%

Conclusion: It seems that even in this selected patient subgroup BC is still heterogeneous disease. The most significant findings in this analysis is the high percentage of triple negative BC registered in 30.7% of PABC, as well as higher than usual HER2 3 positivity, registered in 28% of PABC. The most surprising finding is unexplainable high percentage of inflammatory breast cancer (IBC), registered in 15.3% PABC, that is significantly higher than in general BC population.

Disclosure: All authors have declared no conflicts of interest.